Deciphering Market Trends – A Look at INCY Stock

By Chris Stiles • Wednesday, June 04 10:03 • Permanent Link

Large-cap Health Care company Incyte has moved 0.6% so far today on a volume of 134,355, compared to its average of 2,078,700. In contrast, the S&P 500 index moved 0.0%.

Incyte trades -8.61% away from its average analyst target price of $73.88 per share. The 23 analysts following the stock have set target prices ranging from $52.0 to $96.0, and on average have given Incyte a rating of buy.

Anyone interested in buying INCY should be aware of the facts below:

Incyte's current price is 808.8% above its Graham number of $7.43, which implies that at its current valuation it does not offer a margin of safety
Incyte has moved 13.7% over the last year, and the S&P 500 logged a change of 11.5%
Based on its trailing earnings per share of 0.2, Incyte has a trailing 12 month Price to Earnings (P/E) ratio of 337.6 while the S&P 500 average is 29.3
INCY has a forward P/E ratio of 11.0 based on its forward 12 month price to earnings (EPS) of $6.14 per share
Its Price to Book (P/B) ratio is 3.57 compared to its sector average of 3.19
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis.
Based in Wilmington, the company has 2,617 full time employees and a market cap of $13.07 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.